A small-molecule STING agonist is conjugated to a nanobody that binds to serum albumins to increase tumour accumulation and augment antitumour immunity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
118,99 € per year
only 9,92 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hu, J. et al. Nature 616, 806–813 (2023).
Bakhoum, S. F. et al. Nature 553, 467–472 (2018).
Chen, Q. et al. Nature 533, 493–498 (2016).
Kimmel, B. R. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-025-01400-0 (2025).
Meric-Bernstam, F. et al. Clin. Cancer Res. 28, 677–688 (2022).
Dane, E. L. et al. Nat. Mater. 21, 710–720 (2022).
Dosta, P. et al. Nat. Nanotechnol. 18, 1351–1363 (2023).
Yang, K. et al. Nat. Nanotechnol. 17, 1322–1331 (2022).
Li, S. et al. Nat. Biomed. Eng. 5, 455–466 (2021).
Liu, H. et al. Nature 507, 519–522 (2014).
Fajgenbaum, D. C. & June, C. H. N. Engl. J. Med. 383, 2255–2273 (2020).
Wang, J. et al. Sci. Immunol. 9, eadj3945 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ye, S., Gao, J. Hitchhiking albumin to STING tumours. Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01401-z
Published:
DOI: https://doi.org/10.1038/s41551-025-01401-z
